Stenotrophomonas maltophilia: an emerging global opportunistic pathogen
- PMID: 22232370
- PMCID: PMC3255966
- DOI: 10.1128/CMR.00019-11
Stenotrophomonas maltophilia: an emerging global opportunistic pathogen
Abstract
Stenotrophomonas maltophilia is an emerging multidrug-resistant global opportunistic pathogen. The increasing incidence of nosocomial and community-acquired S. maltophilia infections is of particular concern for immunocompromised individuals, as this bacterial pathogen is associated with a significant fatality/case ratio. S. maltophilia is an environmental bacterium found in aqueous habitats, including plant rhizospheres, animals, foods, and water sources. Infections of S. maltophilia can occur in a range of organs and tissues; the organism is commonly found in respiratory tract infections. This review summarizes the current literature and presents S. maltophilia as an organism with various molecular mechanisms used for colonization and infection. S. maltophilia can be recovered from polymicrobial infections, most notably from the respiratory tract of cystic fibrosis patients, as a cocolonizer with Pseudomonas aeruginosa. Recent evidence of cell-cell communication between these pathogens has implications for the development of novel pharmacological therapies. Animal models of S. maltophilia infection have provided useful information about the type of host immune response induced by this opportunistic pathogen. Current and emerging treatments for patients infected with S. maltophilia are discussed.
Figures
Comment in
-
Growing resistance in Stenotrophomonas maltophilia?Am J Health Syst Pharm. 2019 Dec 2;76(24):2004-2005. doi: 10.1093/ajhp/zxz247. Am J Health Syst Pharm. 2019. PMID: 31789358 No abstract available.
Similar articles
-
New strategies against Stenotrophomonas maltophilia: a serious worldwide intrinsically drug-resistant opportunistic pathogen.Expert Rev Anti Infect Ther. 2014 Jan;12(1):1-4. doi: 10.1586/14787210.2014.864553. Epub 2013 Dec 4. Expert Rev Anti Infect Ther. 2014. PMID: 24308713
-
Antimicrobial susceptibility pattern of Burkholderia cepacia complex & Stenotrophomonas maltophilia over six years (2007-2012).Indian J Med Res. 2015 Oct;142(4):492-4. doi: 10.4103/0971-5916.169225. Indian J Med Res. 2015. PMID: 26609043 Free PMC article. No abstract available.
-
Molecular epidemiology and risk factors of Stenotrophomonas maltophilia infections in a Chinese teaching hospital.BMC Microbiol. 2020 Sep 29;20(1):294. doi: 10.1186/s12866-020-01985-3. BMC Microbiol. 2020. PMID: 32993493 Free PMC article.
-
Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment.Expert Rev Anti Infect Ther. 2011 Apr;9(4):471-88. doi: 10.1586/eri.11.24. Expert Rev Anti Infect Ther. 2011. PMID: 21504403 Review.
-
Stenotrophomonas maltophilia: From trivial to grievous.Indian J Med Microbiol. 2017 Oct-Dec;35(4):469-479. doi: 10.4103/ijmm.IJMM_16_430. Indian J Med Microbiol. 2017. PMID: 29405136 Review.
Cited by
-
Global mapping of antibiotic resistance rates among clinical isolates of Stenotrophomonas maltophilia: a systematic review and meta-analysis.Ann Clin Microbiol Antimicrob. 2024 Mar 19;23(1):26. doi: 10.1186/s12941-024-00685-4. Ann Clin Microbiol Antimicrob. 2024. PMID: 38504262 Free PMC article. Review.
-
Inhaled corticosteroids and Stenotrophomonas maltophilia in outpatients with chronic obstructive pulmonary disease: a retrospective cohort study.BMJ Open Respir Res. 2024 Mar 9;11(1):e001929. doi: 10.1136/bmjresp-2023-001929. BMJ Open Respir Res. 2024. PMID: 38460975 Free PMC article.
-
Case series: Stenotrophomonas maltophilia in pediatric oncology patients.Cancer Rep (Hoboken). 2024 Mar;7(3):e1982. doi: 10.1002/cnr2.1982. Epub 2024 Feb 28. Cancer Rep (Hoboken). 2024. PMID: 38419283 Free PMC article.
-
The epidemiology of Stenotrophomonas maltophilia and Achromobacter xylosoxidans infections.Antimicrob Steward Healthc Epidemiol. 2024 Feb 2;4(1):e18. doi: 10.1017/ash.2024.11. eCollection 2024. Antimicrob Steward Healthc Epidemiol. 2024. PMID: 38415099 Free PMC article.
-
Sequencing and description of the genome of a strain of Stenotrophomonas geniculata isolated from a patient infected with COVID-19 at Hospital Regional No.1 de Charo, Michoacán, México.MicroPubl Biol. 2024 Feb 12;2024:10.17912/micropub.biology.001051. doi: 10.17912/micropub.biology.001051. eCollection 2024. MicroPubl Biol. 2024. PMID: 38415072 Free PMC article.
References
-
- Aaron SD, et al. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366:463–471 - PubMed
-
- Adjidé CC, et al. 2010. Stenotrophomonas maltophilia and Pseudomonas aeruginosa water associated microbiologic risk assessment in Amiens' University Centre. Pathol. Biol. (Paris) 58:e1–e15 doi: 10.1016/j.patbio.2009.07.006 - DOI - PubMed
-
- Adjidé CC, et al. 2010. A sensitive, specific and predictive isolation medium developed for Stenotrophomonas maltophilia study in healthcare settings. Pathol. Biol. (Paris) 58:11–17 - PubMed
-
- Akçakaya AA, et al. 2011. A cluster of acute-onset postoperative endophthalmitis over a 1-month period: investigation of an outbreak caused by uncommon species. Br. J. Ophthalmol. 95:481–484 - PubMed
-
- Akova M, Bonfiglio G, Livermore DM. 1991. Susceptibility to β-lactam antibiotics of mutant strains of Xanthomonas maltophilia with high- and low-level constitutive expression of L1 and L2 β-lactamases. J. Med. Microbiol. 35:208–213 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
